# TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.

> **NCT05195450** · NA · RECRUITING · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 200 (estimated)

## Conditions studied

- Non-cirrhotic, Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir alafenamide fumarate

## Key facts

- **NCT ID:** NCT05195450
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-23
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195450, "TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05195450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*